The ability of Hepascore to predict liver fibrosis in chronic liver disease: A meta-analysis by Huang, Yi et al.
The University of Notre Dame Australia
ResearchOnline@ND
Health Sciences Papers and Journal Articles School of Health Sciences
2016
The ability of Hepascore to predict liver fibrosis in chronic liver disease: A meta-
analysis
Yi Huang
Leon A. Adams
John Joseph
Max Bulsara
University of Notre Dame Australia, max.bulsara@nd.edu.au
Gary P. Jeffrey
Follow this and additional works at: http://researchonline.nd.edu.au/health_article
Part of the Life Sciences Commons, and the Medicine and Health Sciences Commons
This article was originally published as:
Huang, Y., Adams, L. A., Joseph, J., Bulsara, M., & Jeffrey, G. P. (2016). The ability of Hepascore to predict liver fibrosis in chronic liver
disease: A meta-analysis. Liver International, Early View (Online First).
Original article available here:
http://onlinelibrary.wiley.com/doi/10.1111/liv.13116/abstract
This article is posted on ResearchOnline@ND at
http://researchonline.nd.edu.au/health_article/149. For more
information, please contact researchonline@nd.edu.au.
This is the peer reviewed version of the following article: 
Huang, Y., Adams, L., Joseph, J., Bulsara, M., & Jeffrey, G. (2016). The ability of Hepascore to 
predict liver fibrosis in chronic liver disease: a meta-analysis. Liver International, Early View 
(Online First). doi:10.111/liv.13116 
which has been published in final form 
at http://onlinelibrary.wiley.com/doi/10.1111/liv.13116/abstract  
This article may be used for non-commercial purposes in accordance with Wiley Terms and 
Conditions for self-archiving. 
A
cc
ep
te
d 
A
rt
ic
le
This article has been accepted for publication and undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process, which may 
lead to differences between this version and the Version of Record. Please cite this article as 
doi: 10.1111/liv.13116 
This article is protected by copyright. All rights reserved. 
Received Date : 10-Feb-2016 
Revised Date   : 22-Feb-2016 
Accepted Date : 08-Mar-2016 
Article type      : Original Articles 
 
 
The Ability of Hepascore to Predict Liver Fibrosis in Chronic Liver Disease: a Meta-
analysis 
 
Yi Huang
1,2
, Leon A Adams
1,2
, John Joseph
3
, Max Bulsara
4
, Gary P Jeffrey
1,2
 
1. School of Medicine and Pharmacology, University of Western Australia, Perth, Australia. 
2. Department of Gastroenterology and Hepatology, Sir Charles Gairdner Hospital, Perth, 
Australia. 3. Department of Biochemistry, PathWest Laboratory Medicine, QEII Medical 
Centre, Perth, Australia. 4. Institute of Health Research, University of Notre Dame, Perth, 
Australia.  
 
Contact information:  Prof Gary P Jeffrey MB BS, MD, FRACP, FRCP 
Address: School of Medicine and Pharmacology, University of Western Australia, 5
th
 Floor, 
Harry Perkins Institute of Medical Research, 6 Verdun Street, Nedlands, 6009.  
Email: gary.jeffrey@uwa.edu.au.         
Phone: +61 8 6151 0917   
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
List of Abbreviations: HCV: chronic hepatitis C virus; HBV: chronic hepatitis B; ALD: 
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ABSTRACT 
Background & Aims: Hepascore is a serum model that was developed to assess the severity 
of liver fibrosis. It has been well validated in common causes of chronic liver disease. This 
study performed a meta-analysis to evaluate the pooled diagnostic performance of Hepascore 
and to compare it for different aetiologies of chronic liver disease.  
Methods: Two reviewers searched electronic databases from October 2005 to September 
2015 for studies that evaluated the diagnostic performance of Hepascore for liver fibrosis in 
chronic liver disease.  
Results: 21 studies were included. The AUROC was adjusted according to the distribution of 
fibrosis stages. The mean adjusted AUROC was 0.83 (95%CI, 0.81-0.85) for significant 
fibrosis, 0.89 (95%CI, 0.85-0.92) for advance fibrosis and 0.93 (95%CI, 0.91-0.95) for 
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cirrhosis. A cut point of 0.50-0.55 achieved a summary sensitivity of 70% and a summary 
specificity of 79% to predict significant fibrosis. A cut point of 0.50-0.61 had a summary 
sensitivity of 81% and a summary specificity of 74% to predict advanced fibrosis. A cut point 
of 0.80-0.84 had a summary sensitivity of 72% and a summary specificity of 0.88% to predict 
cirrhosis. The accuracy of Hepascore was similar among all disease aetiologies for the 
prediction of cirrhosis. However, Hepascore had better diagnostic ability for significant and 
advanced fibrosis in chronic hepatitis C, chronic hepatitis B and alcoholic liver disease than 
for non-alcoholic fatty liver disease and HIV co-infected viral hepatitis.  
Conclusions: Hepascore is a clinically useful measure of liver fibrosis in patients with 
common causes of chronic liver disease. 
 
Key words: Hepascore; DANA; liver fibrosis; AUROC 
 
KEY POINT BOX 
 Hepascore has been validated in chronic hepatitis C, chronic hepatitis B, alcoholic 
liver disease and non-alcoholic fatty liver disease.   
 Hepascore had an excellent accuracy to exclude cirrhosis in all four common causes 
of chronic liver disease. 
 Hepascore had good diagnostic performance for significant fibrosis and advanced 
fibrosis in chronic hepatitis C, chronic hepatitis B and alcoholic liver disease. 
 A cut point of 0.50-0.61 is predictive of significant fibrosis and advanced fibrosis and 
a cut point of 0.80-0.84 is predictive of cirrhosis.  
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INTRODUCTION 
Chronic liver disease is a major global health problem. Chronic hepatitis C virus (HCV) 
infection, chronic hepatitis B virus (HBV) infection, alcoholic liver disease (ALD) and non-
alcoholic fatty liver disease (NAFLD) are the main causes of chronic liver disease. Most 
chronic liver diseases have a similar clinical course with a prolonged asymptomatic early 
phase during which liver damage progresses silently and variable late clinical presentation of 
decompensated cirrhosis. The disease prognosis is closely associated with the severity of 
liver fibrosis and the majority of adverse outcomes occur after the development of liver 
cirrhosis [1]. As a result, liver fibrosis severity is currently the most reliable patient 
prognostic measure. Additionally, the measurement of liver fibrosis can help to guide 
important clinical management decisions that include the need for treatment and the initiation 
of hepatocellular carcinoma and liver decompensation surveillance.  
Histopathological staging of liver biopsy has been used as the gold standard for liver fibrosis 
measurement. However liver biopsy is limited in its use due to its invasive nature, sampling 
error and risk of serious complications or death [2]. Furthermore, liver biopsy is inconvenient, 
expensive and not widely accessible to a large number of patients or physicians. Surrogate 
serum fibrosis models that can accurately predict the severity of liver fibrosis are of great 
clinical significance. Compared to liver biopsy, serum fibrosis models have advantages of 
low cost, wide availability, high reproducibility and non-invasive nature. During the last two 
decades, a number of serum fibrosis models have been developed and a few of them have 
been well validated and used in routine clinical practice.  
Hepascore is a serum model that was developed to predict the severity of liver fibrosis in 
patients with chronic hepatitis C [3]. Hepascore includes four biomarkers, namely: alpha2-
macroglobulin, hyaluronic acid, bilirubin and gamma-glutamyl transpeptidase, as well as age 
and gender [3]. After the initial development and validation of Hepascore in chronic hepatitis 
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C, Hepascore has been more widely validated in chronic hepatitis B, ALD and NAFLD to 
detect significant liver fibrosis (Metavir F2, F3, F4), advanced fibrosis (Metavir F3, F4) and 
cirrhosis (Metavir F4). However, no meta-analysis of these studies has been performed. This 
study performed a meta-analysis of all Hepascore validation studies to evaluate the summary 
diagnostic performance of Hepascore and to compare it across different aetiologies of chronic 
liver disease.  
 
MATERIALS AND METHODS 
Literature search strategy 
An electronic search was performed on PubMed and Cochrane library using the key word 
“Hepascore” from October 2005 to September 2015. Studies were included if they met the 
following inclusion criteria: 1) The whole population or a sub-group of patients who had 
chronic hepatitis C with or without HIV co-infection, chronic hepatitis B with or without HIV 
co-infection, ALD, NAFLD or mixed aetiology of chronic liver disease could be extracted 
from the study. 2) Both liver biopsy and Hepascore were performed for patients and the 
diagnostic performance of Hepascore was evaluated. 3) Studies provided the area under ROC 
curve (AUROC) (95% CI) of Hepascore for different fibrosis stages and/or the true positive, 
true negative, false positive and false negative of at least one cut point could be calculated 
from the data. Exclusion criterial included: 1) non-English literature. 2) reviews. 3) 
duplicated cohorts. 4) The target population were patients with liver disease other than 
chronic hepatitis C, chronic hepatitis B, ALD and NAFLD.  
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Study inclusion and quality assessment  
The studies were assessed by two independent reviewers using predetermined inclusion and 
exclusion criteria. The quality of each study was determined by using the validated quality 
assessment of diagnostic accuracy studies (QUADAS) questionnaire [4]. The questionnaire 
included 14 questions that covered use of appropriate patient population and reference 
standard, disease progression bias, verification bias, review bias, clinical review bias, 
incorporation bias, test execution, study withdrawals and indeterminate bias [4]. For each 
question, yes, no or unclear was scored. Disagreements between the two reviewers were 
resolved through further review.  
 
Statistical analysis 
Two approaches were used to evaluate the summary diagnostic performance of Hepascore. 
Firstly, meta-analysis was performed using the random effects model for all included studies 
that provided both AUROC and 95% CI. Previous studies found that the AUROC was 
significantly influenced by the distribution of fibrosis stages [5]. Hence, the AUROC was 
standardized according to the difference between the mean fibrosis stages in advanced 
fibrosis and non-advanced fibrosis groups (DANA) using the formula: adAUROC = 
obAUROC + (0.1056) * (2.5 - DANA) [5]. Meta-analysis was performed for both observed 
AUROC (obAUROC) and adjusted AUROC (adAUROC). ObAUROC and adAUROC of 
Hepascore was compared between different aetiologies of chronic liver disease. Meta-
regression analysis and sensitivity analysis were used to evaluate the influence of seven 
characteristics of individual studies on AUROC, namely: patient inclusion methods (single 
centre vs multicentre), mean biopsy length (<20mm vs ≥20mm), biopsy evaluation (blinded 
vs not blinded), interval time between biopsy and serum collection (within one month vs >1 
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month), serum collection (fasting vs non-fasting), Hyaluronic acid test kit (Corgenix vs other 
kit) and study quality (all question score yes vs one or more questions scored no or unclear ).  
Secondly, a summary ROC (SROC) model was calculated for all included studies from which 
at least one 2X2 table containing true positive, true negative, false positive and false negative 
could be created [6]. Summary sensitivity and specificity of validated cut points to predict 
significant fibrosis, advanced fibrosis and cirrhosis were calculated. The estimated positive 
predictive value (PPV) and negative predictive value (NPV) of each cut point was calculated 
using the observed prevalence.  
 
RESULTS 
Literature search results 
A total of 55 articles were identified from the literature search. 45 were original studies and 
were published in English. 24 studies were excluded for the following reasons: 14 studies did 
not evaluate the diagnostic performance of Hepascore or did not provide sufficient data for 
the meta-analysis; six studies evaluated the utility of Hepascore in other types of liver disease; 
four studies had duplicated cohorts. 21 studies were included in the final analysis. The main 
characteristics of these studies were shown in table 1 [3, 7-27]. A total of 5686 patients were 
included: 3523 had HCV infection, 441 had HCV/HIV co-infection, 588 had HBV infection, 
108 had HBV/HIV co-infection, 321 had ALD, 242 had NAFLD and 463 had mixed 
aetiology of chronic liver disease. 11% patients had Metavir F0 (range: 0-44%), 34% had 
Metavir F1 (range: 11-47%), 25% had Metavir F2 (range 17-40%), 15% had Metavir F3 
(range: 3-25%), 15% had Metavir F4 (range: 6-32%). According to the QUADAS 
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questionnaire, the qualities of the final 21 studies were good to excellent. (table 2). Twenty of 
these used the Metavir staging system as the reference standard.  
 
Diagnostic performance of Hepascore for significant fibrosis 
19 cohorts reported AUROC and 95%CI for significant fibrosis. The mean obAUROC of 
Hepascore was 0.78 (95%CI, 0.76-0.80) and the mean adAUROC was 0.83 (95%CI, 0.81-
0.85) (figure 1). Hepascore had an increased diagnostic accuracy in HCV, HBV, ALD and 
mixed aetiology with a mean obAUROC of 0.80 (95%CI, 0.77-0.82), 0.79 (95%CI, 0.75-
0.83), 0.82 (95%CI, 0.76-0.87) and 0.80 (95C%CI, 0.74-0.86) respectively. Less diagnostic 
accuracy of Hepascore was found for patients with HIV co-infection and NAFLD, with a 
mean obAUROC of 0.73 (95%CI, 0.67-0.79) and 0.73 (95%CI, 0.66-0.80) respectively. 
Compared to obAUROC, most adAUROC’s for different causes of liver disease increased, 
with adAUROC of 0.85 (95%CI, 0.82-0.87) in HCV, 0.84 (95%CI, 0.80-0.88) in HBV, 0.83 
(95%CI, 0.76-0.89) in ALD, 0.80 (95%CI, 0.76-0.84) in HIV co-infection and 0.81 (95%CI, 
0.75-0.87) in mixed aetiologies (figure 1). The diagnostic accuracy for NAFLD remained less 
than other forms of liver disease with adAUROC of 0.74 (95%CI, 0.67-0.81). Significant 
heterogeneity was observed for obAUROC (I
2
=55.6%, p=0.002) and for adAUROC (I
2
=47%, 
p=0.013). Sub-group analysis of heterogeneity was performed according to the causes of 
chronic liver disease. Non-significant heterogeneity of obAUROC was found in chronic 
hepatitis B (I
2
=6.8%, p=0.359), HIV co-infection (I
2
=47%, p=0.152) and ALD (I
2
=7.4%, 
p=0.299), while significant heterogeneity was found in chronic hepatitis C (I
2
=60%, p=0.015). 
Non-significant heterogeneity of adAUROC was found in all analysed causes: chronic 
hepatitis C (I
2
=48.8%, p=0.057), chronic hepatitis B (I
2
=6.5%, p=0.361), HIV co-infection 
(I
2
=0.0%, p=0.625) and ALD (I
2
=27.9%, p=0.239). Sub-group analysis was not performed 
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for NAFLD and mixed aetiologies due to only one study of each cause was available for 
analysis.  
The diagnostic performance of at least one cut point was reported in 18 cohorts and these 
were included in the SROC analysis (table 3). The average prevalence of significant fibrosis 
was 52% (ranged: 41% - 66%). The summary AUROC for all causes of liver disease was 
0.79 (95%CI, 0.76-0.83) and this was similar to the AUROC calculated using the random 
effects model (figure 2A). The summary diagnostic odds ratio (DOR) was 7.3 (5.9-9.1). A cut 
point of 0.50-0.55 was validated in 10 cohorts with a summary sensitivity of 0.70 (95% CI, 
0.60-0.78) and summary specificity of 0.79 (95% CI, 0.72-0.85). A lower cut point of 0.31-
0.34 was validated in four cohorts with a summary sensitivity of 0.75 (95%CI, 0.60-0.86) and 
a summary specificity of 0.65 (95%CI, 0.57-0.73). Using the average observed prevalence of 
significant fibrosis (52%) in the included studies, the cut point of 0.5-0.55 had an estimated 
PPV of 0.78 and an estimated NPV of 0.71. The cut point of 0.31-0.34 had an estimated PPV 
of 0.70 and an estimated NPV of 0.71.  
 
Diagnostic performance of Hepascore for advanced fibrosis 
16 cohorts reported AUROC and 95%CI for advanced fibrosis. The mean obAUROC was 
0.84 (95%CI, 0.81-0.87) and the mean adAUROC was 0.89 (95%CI, 0.85-0.92) (figure 3). 
Hepascore achieved a higher diagnostic accuracy in HCV and HBV with a mean obAUROC 
of 0.85 (95%CI, 0.80-0.90) and 0.86 (95%CI, 0.79-0.94) respectively. The obAUROC was 
0.78 (95%CI, 0.72-0.85) for HIV co-infection, 0.83 (95%CI, 0.74-0.93) for ALD and 0.81 
(95%CI, 0.73-0.90) for NAFLD. A similar pattern was found using adAUROC, with the 
mean adAUROC of 0.90 (95%CI, 0.86-0.95) in HCV, 0.91 (95%CI, 0.84-0.98) in HBV, 0.86 
(95%CI, 0.82-0.90) in HIV co-infection, 0.84 (95%CI, 0.74-0.93) in ALD, 0.83 (95%CI, 
0.74-0.91) in NAFLD and 0.73 (95%CI, 0.62-0.83) in mixed liver disease aetiologies. 
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Significant heterogeneity was observed for both obAUROC (I
2
=83.5%, p<0.001) and 
adAUROC (I
2
=81.1%, p<0.001). Sub-group analysis showed that significant heterogeneity of 
both obAUROC and adAUROC was found in HCV (obAUROC: I
2
=89%, p<0.001, 
adAUROC: I
2
=85.7%, p<0.001) and HBV (obAUROC: I
2
=80.8%, p=0.001, adAUROC: 
I
2
=76.9%, p=0.005) but not for HIV co-infection (obAUROC: I
2
=43.7%, p=0.183, 
adAUROC: I
2
=0.0%, p=0.646). Sub-group analysis of heterogeneity was not performed for 
ALD, NAFLD and mixed aetiologies due to the presence of one study in each subgroup.  
14 cohorts validated cut points to predict advanced fibrosis and these were included in the 
SROC analysis (table 3). The average prevalence of advanced fibrosis was 27% (ranged: 19% 
- 38%). The summary AUROC was 0.84 (95%CI, 0.81-0.87) and summary DOR was 11.9 
(95%CI, 9.0 - 15.7) (figure 2B). A cut point of 0.50-0.61 was validated in seven cohorts with 
a summary sensitivity of 0.81 (95% CI, 0.71-0.87) and a summary specificity of 0.74 (95% 
CI, 0.72-0.77). Using the average observed prevalence of advanced fibrosis (27%), the same 
cut point had an estimated PPV of 0.54 and an estimated NPV of 0.91. 
 
Diagnostic performance of Hepascore for cirrhosis 
15 cohorts reported AUROC and 95%CI for cirrhosis. The mean obAUROC was 0.88 
(95%CI, 0.86-0.90) and the mean adAUROC was 0.93 (95%CI, 0.91-0.95) (figure 4). 
Excellent accuracy was observed in all aetiologies of chronic liver disease with obAUROC of 
0.89 (95%CI, 0.88-0.91) in HCV, 0.88 (95%CI, 0.83-0.92) in HBV, 0.87 (95%CI, 0.79-0.96) 
for HIV co-infection, 0.85 (95%CI, 0.70-1.00) for ALD, 0.91 (95%CI, 0.83-0.99) for 
NAFLD. The adAUROC was 0.95 (95%CI, 0.93-0.97) in HCV, 0.92 (95%CI, 0.87-0.98) in 
HBV, 0.95 (95%CI, 0.90-0.99) for HIV co-infection, 0.86 (95%CI, 0.70-1.00) for ALD and 
0.92 (95%CI, 0.84-1.00) for NAFLD. Hepascore had less diagnostic accuracy in patients with 
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mixed aetiologies with obAUROC of 0.81 (95%CI, 0.75-0.86) and adAUROC of 0.82 
(95%CI, 0.76-0.88). Significant heterogeneity was observed for both obAUROC (I
2
=44.2%, 
p=0.034) and adAUROC (I
2
=62.2%, p=0.001). Sub-group analysis found significant 
heterogeneity of obAUROC in HIV co-infection (I
2
=82.2%, p=0.018) and ALD (I
2
=78.9%, 
p=0.029) but not in HCV (I
2
=0.0%, p=0.671) and HBV (I
2
=0.0%, p=0.380). Significant 
heterogeneity of adAUROC was only found in ALD (I
2
=81.2%, p=0.021) but not in chronic 
hepatitis C (I
2
=29.1%, p=0.217), chronic hepatitis B (I
2
=22.3%, p=0.276) and HIV co-
infection (I
2
=26.1%, p=0.245). Sub-group analysis of heterogeneity was not performed for 
NAFLD and mixed aetiologies due to the presence of one study in each subgroup. 
13 cohorts validated cut points to predict cirrhosis and were included in the SROC analysis 
(table 3). The average prevalence of advanced fibrosis was 13% (ranged: 6% - 31%). The 
summary AUROC was 0.90 (95%CI, 0.88-0.93) and the summary DOR was 25.3 (95%CI, 
17.1-37.5) (figure 2C). A cut point of 0.80-0.84 was validated in seven cohorts with a 
summary sensitivity of 0.72 (95% CI, 0.64-0.79) and a summary specificity of 0.88 (95% CI, 
0.0.85-0.91). Using the average observed prevalence of cirrhosis (13%), the same cut point 
had an estimated PPV of 0.47 and an estimated NPV of 0.95. 
 
Sensitivity analysis 
A sensitivity analysis was performed to test the effect of study characteristics on the 
adAUROC of Hepascore.  No significant effect on adAUROC was found when patient 
inclusion methods, mean biopsy length, biopsy evaluation, interval time between biopsy and 
serum collection, timing of serum collection, hyaluronic acid test kit and study quality were 
analysed (table 4). 
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DISCUSSION 
This meta-analysis reviewed 21 studies that evaluated the diagnostic performance of 
Hepascore for measuring the severity of liver fibrosis in chronic liver disease. Duplicate 
cohorts were excluded. The strength of this meta-analysis was that these studies included 
worldwide populations of the most common aetiologies of chronic liver disease, namely 
chronic hepatitis C, chronic hepatitis B, ALD and NAFLD. Standardization of the AUROC 
according to the distribution of liver fibrosis stages amongst cohorts allowed a more accurate 
comparison of the diagnostic performance of Hepascore for different aetiologies of chronic 
liver disease.  
Hepascore had an excellent accuracy to predict cirrhosis for all aetiologies of chronic liver 
disease with an adAUROC of 0.95 for chronic hepatitis C, 0.92 for chronic hepatitis B, 0.86 
for ALD, 0.92 for NAFLD and 0.95 for HIV co-infected chronic hepatitis. Meta-analysis of 
chronic hepatitis C and chronic hepatitis B found that Hepascore also had an excellent 
adAUROC for significant fibrosis, 0.85 and 0.84 respectively and for advanced fibrosis, 0.90 
and 0.91 respectively.  In ALD, NAFLD and HIV co-infected chronic hepatitis the diagnostic 
performance of Hepascore was good for significant fibrosis and advanced fibrosis. The 
adAUROC for significant fibrosis in ALD, NAFLD and HIV co-infection hepatitis was 0.83, 
0.74 and 0.80 respectively and for advanced fibrosis the adAUROC was 0.84, 0.83 and 0.86 
respectively. Apart from NAFLD, all other chronic liver disease aetiologies had an increased 
adAUROC compared with obAUROC. The adAUROC according to DANA was developed 
in chronic hepatitis C, but we predict that the fibrosis distribution for other liver diseases has 
a similar effect on AUROC.   
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The diagnostic performance of validated cut points for significant fibrosis, advanced fibrosis 
and cirrhosis were also evaluated for all causes of chronic liver disease. The cut points 
proposed in the original study of Hepascore were those most commonly validated in 
subsequent studies. A cut point of 0.50-0.55 had a summary sensitivity of 70%, summary 
specificity of 79%, an estimated PPV of 0.78 and an estimated NPV of 0.71 to predict 
significant fibrosis. A cut point of 0.50-0.61 had a summary sensitivity of 81%, a summary 
specificity of 74%, an estimated PPV of 0.54 and an estimated NPV of 0.91 to predict 
advanced fibrosis. A cut point of 0.80-0.84 had a summary sensitivity of 72%, a summary 
specificity of 0.88%, an estimated PPV of 0.47 and an estimated NPV of 0.91 to predict 
cirrhosis. These results were similar to those reported in the original study. Hepascore had the 
most accurate ability to excluded advanced fibrosis and cirrhosis with an estimated NPV of 
0.91 for both.  
Significant heterogeneity of obAUROC was found between all studies. This was 
heterogeneity was reduced but still remained significant after adjustment of the AUROC for 
DANA. This suggested that heterogeneity might be partly caused by the different distribution 
of fibrosis stages between studies. Subgroup analysis of disease aetiology found that 
heterogeneity of adAUROC was no longer significant within: HCV, HBV, HIV co-infection 
and ALD to predict significant fibrosis; in HIV co-infection to predict advanced fibrosis and 
in HCV, HBV, HIV co-infection to predict cirrhosis. This suggests that in addition to fibrosis 
distribution different aetiologies of chronic liver disease was another cause of heterogeneity 
between studies. Meta-regression analysis and sensitivity analysis was performed using seven 
pre-defined study characteristics. However, none of these characteristics showed a significant 
effect on AUROC. Others had previously found that blinded biopsy reviewing and 
histological staging system had an effect on the AUROC of other serum models [28]. The 
small number of studies that included in each subgroup made further analysis of the source of 
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heterogeneity impossible. Another limitation of this study was the potential bias that may 
have been a result of only including published full length articles to ensure adequate and 
comprehensive assessment of study quality.   
In summary, this study confirmed that Hepascore is a useful measure of the severity of liver 
fibrosis in patients with the common causes of chronic liver disease. Hepascore had an 
excellent accuracy to exclude cirrhosis in all four causes of chronic liver disease and had 
good diagnostic performance for significant fibrosis and advanced fibrosis in chronic 
hepatitis C, chronic hepatitis B and alcoholic liver disease. 
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Table 1. Characteristics of studies included in the analysis. 
Cohorts year aetiology Country centre No. 
mean 
age 
male 
(%) 
Staging 
system 
F0 
(%)  
F1 
(%) 
F2 
(%) 
F3 
(%) 
F4 
(%) 
Mean 
biopsy 
size 
(mm) 
Serum 
collection 
Interval 
days 
DANA 
Adams -training [3] 2005 HCV Australia Single centre 117 40 68 Metavir 20 37 25 13 6 13 no fasting - 1.92 
Adams-validation [3] 2005 HCV Australia Multi centre 104 41 73 Metavir 16 27 34 7 16 13 no fasting - 2.07 
Bourliere [26] 2008 HCV France Multi centre 467 47 59 Metavir 15 36 22 20 7 20 no fasting 0 2.00 
Cales [22], Boursier [17] 2008-9 HCV France Multi centre 1056 46 60 Metavir 4 43 27 14 11 21 no fasting - 1.79 
Becker [14] 2009 HCV US Single centre 391 50 70 Metavir 16 34 15 16 19 16 no fasting <90 2.41 
Guéchot [13] 2010 HCV France Multi centre 512 50 60 Metavir 7 45 18 15 15 25 fasting <60 2.06 
Lee [10] 2010 HCV Australia Single centre 95 45 63 Scheuer  -  -  -  -  - 15 no fasting < 210 - 
Kalantari [25] 2011 HCV Iran Single centre 80 35 85 Metavir 15 31 25 9 20 - no fasting - 2.23 
Crisan [21] 2012 HCV Romania Single centre 446 49 38 Metavir 7 30 36 18 9 11 fasting 0 1.76 
Leroy [24] 2014 HCV France Single centre 255 47 57 Metavir 15 38 26 11 11 24 fasting 0 1.97 
Cacoub [7] 2008 HCV/HIV France Multi centre 272 40 72 Metavir 0 25 40 25 10 19 fasting  - 1.60 
Cales [9] 2010 HCV/HIV France Multi centre 169 41 65 Metavir 8 26 33 13 20 25 fasting <90 2.03 
Wu [20] 2010 HBV China Single centre 78 33 84 Metavir 17 42 17 13 12 18 no fasting - 2.16 
Raftopoulos [27] 2011 HBV Australia Multi centre 179 42 71 Metavir 15 43 20 14 8 21 no fasting <180 1.99 
Basar [19] 2013 HBV Turkey Single centre 76 45 45 Metavir 12 21 29 21 17 - no fasting 0 2.18 
Leroy [24] 2014 HBV France Single centre 255 40 72 Metavir 15 38 26 11 11 25 fasting 0 1.97 
Bottero [18] 2009 HBV/HIV France Multi centre 108 42 90 Metavir 10 33 26 16 15 17 no fasting <180 2.04 
Naveau [15] 2008 ALD France Single centre 218 47 78 Metavir 7 30 22 10 31 15 no fasting <30 2.34 
Nguyen-Khac [12] 2008 ALD France Single centre 103 53 74 Metavir 8 17 23 19 32 12 no fasting 0 2.42 
Adams [16] 2011 NAFLD Australia Multi centre 242 47 60 Metavir 36 24 18 12 10 - no fasting 0 2.38 
Boursier [8] 2009 Mixed France Multi centre 390 52 68 Metavir 7 18 23 20 31 - no fasting  - 2.39 
Costelloe [11] 2015 Mixed UK Single centre 73 51 62 Metavir 44 11 12 3 30 - no fasting 0 3.19 
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Table 2. Quality assessment of included studies.  
 
 
 
Author, year 
Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 Q12 Q13 Q14 
Spectrum 
bias 
Selection 
criteria 
Appropriate 
reference 
standard 
Disease 
progression 
bias 
Partial 
verification 
bias 
Differential 
verification 
bias 
Incorpor
ation 
bias 
Test 
execution 
details 
Reference 
execution 
details 
Test 
review 
bias 
Diagnostic 
review bias 
Clinical 
review 
bias 
Interme
diate 
results 
withdra
ws 
Adams, 2005[3] yes yes yes yes yes yes yes yes yes yes yes yes yes yes 
Cales, 2008 [22] yes yes yes unclear yes yes yes yes yes yes unclear yes yes yes 
Bourliere, 2008 [26] yes yes unclear yes yes yes yes yes yes yes unclear yes yes yes 
Boursier, 2009 [17] yes yes yes unclear yes yes yes unclear yes yes unclear yes yes yes 
Becker, 2009  [14] yes yes yes yes yes yes yes yes yes yes yes yes yes yes 
Guéchot, 2010 [13] yes yes yes yes yes yes yes yes yes yes yes yes yes yes 
Lee, 2010  [10] yes unclear unclear yes yes yes yes yes yes yes unclear yes yes yes 
Kalantari, 2011 [25] yes no yes unclear yes yes yes yes yes yes unclear yes yes yes 
Crisan, 2012  [21] yes yes yes yes yes yes yes unclear yes yes yes yes yes yes 
Leroy, 2014  [24] yes yes yes yes yes yes yes yes yes yes yes yes yes yes 
Cacoub, 2008  [7] yes yes yes yes yes yes yes unclear yes yes yes yes yes yes 
Cales, 2010 [9] yes yes yes yes yes yes yes yes yes yes yes yes yes yes 
Wu, 2010 [20] yes yes unclear unclear yes yes yes yes yes yes unclear yes yes yes 
Raftopoulos, 2011 
[27] 
yes yes yes yes yes yes yes yes yes yes yes yes yes yes 
Basar, 2013  [19] yes yes yes yes yes yes yes yes yes yes yes yes yes yes 
Bottero, 2009 [18] yes unclear yes yes yes yes yes yes unclear yes yes yes yes yes 
Naveau, 2008 yes yes yes yes yes yes yes yes yes yes yes yes yes yes 
Nguyen-Khac, 2008  
[12] 
no yes yes yes yes yes yes unclear yes yes yes yes yes yes 
Adams, 2011 [16] yes yes yes yes yes yes yes yes yes yes yes yes yes yes 
Boursier, 2009  [8] no unclear yes yes yes yes yes unclear yes yes unclear yes yes yes 
Costelloe, 2015  [11] no no unclear unclear yes yes yes yes yes yes yes yes yes yes 
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Table 3. Validated cut points of Hepascore by included studies.  
 
 
 
 
Cohorts Year Aetiology 
Significant fibrosis Advanced fibrosis Cirrhosis 
Cut 
point 
Sen Spe 
Cut 
point 
Sen Spe 
Cut 
point 
Sen Spe 
Adams -training [3] 2005 HCV 0.5 0.67 0.92 0.50 0.95 0.81 0.84 0.71 0.84 
Adams-validation [3] 2005 HCV 0.5 0.63 0.89 0.50 0.88 0.74 0.84 0.71 0.89 
Bourliere [26] 2008 HCV 0.5 0.63 0.86 - - - 0.84 0.71 0.88 
Cales [22], Boursier [17] 2008-9 HCV 0.47 0.66 0.79 0.50 0.82 0.71 0.80 0.80 0.83 
Becker [14] 2009 HCV 0.55 0.82 0.65 0.80 0.72 0.77 - - - 
Guéchot [13] 2010 HCV 0.5 0.77 0.70 0.60 0.80 0.70 0.75 0.86 0.74 
Lee [10] 2010 HCV 0.5 0.77 0.79 - - - - - - 
Kalantari [25] 2011 HCV 0.34 0.67 0.56 0.61 0.82 0.86 0.84 1.00 0.97 
Crisan [21] 2012 HCV 0.34 0.57 0.72 0.61 0.61 0.73 - - - 
Leroy [24] 2014 HCV 0.5 0.52 0.85 0.47 0.79 0.85 0.84 0.60 0.89 
Cales [9] 2010 HCV/HIV 0.31 0.90 0.59 - - - - - - 
Wu [20] 2010 HBV 0.5 0.88 0.50 - - - - - - 
Raftopoulos [27] 2011 HBV 0.52 0.77 0.76 0.72 0.68 0.85 0.88 0.87 0.86 
Basar [19] 2013 HBV 0.32 0.78 0.68 0.50 0.71 0.79 0.52 0.85 0.75 
Leroy [24] 2014 HBV 0.5 0.42 0.84 0.42 0.75 0.71 0.84 0.56 0.92 
Bottero [18] 2009 HBV/HIV 0.48 0.67 0.68 0.76 0.72 0.87 0.9 0.80 0.89 
Naveau [15] 2008 ALD 0.25 0.90 0.37 - - - 0.97 0.90 0.87 
Adams [16] 2011 NAFLD 0.44 0.51 0.88 0.37 0.76 0.84 0.7 0.87 0.89 
Costelloe  [11] 2015 Mixed - - - 0.99 0.79 0.74 - - - 
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Table 4. Sensitivity analysis of study characteristics. 
Characteristic 
Significant fibrosis Advanced fibrosis Cirrhosis 
No.  AdAUROC 
(95%CI) 
No. AdAUROC 
(95%CI) 
No. AdAUROC 
(95%CI) 
All  19 0.83 (0.81-0.85) 16 0.89 (0.85-0.92) 15 0.93 (0.91-0.95) 
Patients inclusion        
     single centre 9 0.82 (0.80-0.85) 8 0.87 (0.81-0.94) 6 0.92 (0.87-0.97) 
     multicentre 10 0.83 (0.81-0.86) 8 0.89 (0.87-0.91) 9 0.93 (0.91-0.96) 
Mean biopsy length       
      <20 mm 9 0.82 (0.79-0.85) 7 0.90 (0.84-0.97) 6 0.94 (0.90-0.98) 
      ≥20 mm 7 0.85 (0.84-0.87) 6 0.93 (0.88-0.89) 6 0.95 (0.93-0.97) 
Biopsy evaluation       
      blinded 15 0.83 (0.81-0.84) 13 0.87 (0.83-0.91) 12 0.93 (0.91-0.96) 
      not blinded 4 0.86 (0.84-0.88) 3 0.93 (0.88-0.98) 3 0.92 (0.85-0.99) 
Interval time        
      ≤1 month 9 0.81 (0.78-0.84) 8 0.86 (0.83-0.89) 7 0.93 (0.90-0.95) 
      > 1 month 10 0.85 (0.83-0.87) 8 0.91 (0.87-0.96) 7 0.94 (0.90-0.98) 
Serum collection       
     fasting  6 0.82 (0.79-0.85) 5 0.86 (0.82-0.90) 4 0.92 (0.90-0.95) 
     non-fasting  13 0.84 (0.82-0.86) 11 0.90 (0.86-0.94) 11 0.93 (0.90-0.96) 
HA test kit       
     Corgenix 11 0.84 (0.81-0.86) 9 0.91 (0.88-0.94) 9 0.96 (0.94-0.97) 
     other kits 4 0.85 (0.82-0.88) 4 0.86 (0.76-0.96) 3 0.92 (0.90-0.95) 
QUADAS score       
     all scored yes 10 0.84 (0.81-0.86) 7 0.90 (0.85-0.95) 8 0.94 (0.91-0.96) 
     not all scored yes 9 0.82 (0.80-0.85) 9 0.87 (0.83-0.92) 7 0.92 (0.88-0.96) 
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FIGURE LEGENDS:  
Figure 1. ObAUROC and adAUROC of Hepascore to predict significant fibrosis. 
Figure 2. SROC curves of Hepascore. (A): SROC curve for significant fibrosis. (B): SROC 
curve for advanced fibrosis. (C): SROC curve for cirrhosis.  
Figure 3. ObAUROC and adAUROC of Hepascore to predict advanced fibrosis. 
Figure 4. ObAUROC and adAUROC of Hepascore to predict cirrhosis. 
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